TiGenix to present at the 7th TERMIS-EU Conference in Davos, Switzerland

PRESS RELEASE

TiGenix to present at the 7^th TERMIS-EU Conference in Davos, Switzerland

Leuven (BELGIUM) - June 23, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, today announces that Dr. Marie Paule Richard, Chief Medical Officer of TiGenix, will be speaking at the 7^th TERMIS-EU Industry Day taking place from June 26-30, 2017 at the Davos Conference Center, Switzerland.

Dr. Richard will give a presentation at an Industry Symposium on June 28 as part of a session entitled, Clinical evaluation road map and clinical development strategies.

During the coming months, representatives of TiGenix will also be attending the following conferences:

PDA-Advanced Therapy Medicinal Products
Date:                            June 27-28, 2017
Venue:                         SH Valencia Palace, Valencia, Spain
Attendee:                      Dr. Wilfried Dalemans, Chief Technical Officer, TiGenix NV
                              
European Society of Cardiology (ESC) Congress
Date:                            August 26-30, 2017
Venue:                         Fira Gran Via, Barcelona, Spain
Attendee:                      Inmaculada Gilaberte Asin, Clinical Development Director & Manuel Luque, Senior Clinical Project Manager Allo-CSC 01, TiGenix SAU

Annual Symposium of the International Sepsis Forum
Date:                            11-13 September, 2017
Venue:                         Institut Pasteur, Paris, France
Attendee:                      Jesus Gonzalez, Clinical Development Director Cx611, TiGenix SAU

Congress of the European Shock Society.
Date:                            13-15 September, 2017
Venue:                         Institut Pasteur, Paris, France
Attendee:                      Jesus Gonzalez, Clinical Development Director Cx611, TiGenix SAU

For more information

Claudia D'Augusta
Chief Financial Officer

T: [phone]

[e-mail]

About TiGenix

TiGenix NV (Euronext Brussels and NASDAQ: TIG) is an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions.

TiGenix lead product, Cx601, has successfully completed a European Phase III clinical trial for the treatment of complex perianal fistulas - a severe, debilitating complication of Crohn's disease. Cx601 has been filed for regulatory approval in Europe and a global Phase III trial intended to support a future U.S. Biologic License Application (BLA) started in 2017. TiGenix has entered into a licensing agreement with Takeda, a global pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to develop and commercialize Cx601 for complex perianal fistulas outside the U.S. TiGenix' second adipose-derived product, Cx611, is undergoing a Phase I/II trial in severe sepsis - a major cause of mortality in the developed world. Finally, AlloCSC-01, targeting acute ischemic heart disease, has demonstrated positive results in a Phase I/II trial in acute myocardial infarction (AMI). TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain). For more information, please visit http://www.tigenix.com.